Copeptin as a marker for severity and prognosis of aneurysmal subarachnoid hemorrhage

Fung, Christian; De Marchis, Gian Marco; Katan, Mira; Seiler, Marleen; Arnold, Marcel; Gralla, Jan; Raabe, Andreas; Beck, Jürgen

Abstract: BACKGROUND: Grading of patients with aneurysmal subarachnoid hemorrhage (aSAH) is often confounded by seizure, hydrocephalus or sedation and the prediction of prognosis remains difficult. Recently, copeptin has been identified as a serum marker for outcomes in acute ischemic stroke and intracerebral hemorrhage (ICH). We investigated whether copeptin might serve as a marker for severity and prognosis in aSAH. METHODS: Eighteen consecutive patients with aSAH had plasma copeptin levels measured with a validated chemiluminescence sandwich immunoassay. The primary endpoint was the association of copeptin levels at admission with the World Federation of Neurological Surgeons (WFNS) grade score after resuscitation. Levels of copeptin were compared across clinical and radiological scores as well as between patients with ICH, intraventricular hemorrhage, hydrocephalus, vasospasm and ischemia. RESULTS: Copeptin levels were significantly associated with the severity of aSAH measured by WFNS grade (P = 0.006), the amount of subarachnoid blood (P = 0.03) and the occurrence of ICH (P = 0.02). There was also a trend between copeptin levels and functional clinical outcome at 6-months (P = 0.054). No other clinical outcomes showed any statistically significant association. CONCLUSIONS: Copeptin may indicate clinical severity of the initial bleeding and may therefore help in guiding treatment decisions in the setting of aSAH. These initial results show that copeptin might also have prognostic value for clinical outcome in aSAH.

DOI: https://doi.org/10.1371/journal.pone.0053191
Copeptin as a Marker for Severity and Prognosis of Aneurysmal Subarachnoid Hemorrhage

Christian Fung1, Gian Marco De Marchis2, Mira Katan3, Marleen Seiler4, Marcel Arnold2, Jan Gralla5, Andreas Raabe1, Jürgen Beck1*

1 Department of Neurosurgery, Bern University Hospital, Bern, Switzerland, 2 Department of Neurology, Bern University Hospital, Bern, Switzerland, 3 Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, United States of America, 4 Thermo Fisher Scientific, Thermofisher Scientific, Clinical Diagnostics, Henningsdorf, Germany, 5 Institute for Diagnostic and Interventional Neuroradiology, Bern University Hospital, Bern, Switzerland

Abstract

Background: Grading of patients with aneurysmal subarachnoid hemorrhage (aSAH) is often confounded by seizure, hydrocephalus or sedation and the prediction of prognosis remains difficult. Recently, copeptin has been identified as a serum marker for outcomes in acute ischemic stroke and intracerebral hemorrhage (ICH). We investigated whether copeptin might serve as a marker for severity and prognosis in aSAH.

Methods: Eighteen consecutive patients with aSAH had plasma copeptin levels measured with a validated chemiluminescence sandwich immunoassay. The primary endpoint was the association of copeptin levels at admission with the World Federation of Neurological Surgeons (WFNS) grade score after resuscitation. Levels of copeptin were compared across clinical and radiological scores as well as between patients with ICH, intraventricular hemorrhage, hydrocephalus, vasospasm and ischemia.

Results: Copeptin levels were significantly associated with the severity of aSAH measured by WFNS grade (P = 0.006), the amount of subarachnoid blood (P = 0.03) and the occurrence of ICH (P = 0.02). There was also a trend between copeptin levels and functional clinical outcome at 6-months (P = 0.054). No other clinical outcomes showed any statistically significant association.

Conclusions: Copeptin may indicate clinical severity of the initial bleeding and may therefore help in guiding treatment decisions in the setting of aSAH. These initial results show that copeptin might also have prognostic value for clinical outcome in aSAH.

Introduction

For assessment of the severity of aneurysmal subarachnoid hemorrhage (aSAH), the World Federation of Neurological Surgeons (WFNS) grade is the current gold standard [1]. The condition of patients with aSAH may however be confounded by seizure, hydrocephalus or sedation [2]. Treatment decisions such as occlusion of an aneurysm are based on clinical grading [1]. Prediction of outcome remains difficult and complicates decision-making for active treatment [3]. Copeptin has evolved as a serum marker for the severity of disease and outcome of patients in spontaneous intracerebral hemorrhage (ICH), ischemic stroke and sepsis [4,5,6]. It is released in an equimolar ratio with vasopressin from a common precursor protein, pre-provasopressin [7]. Vasopressin is a hypothalamic hormone that is stimulated by adrenocorticotrophic hormone (ACTH) and production of cortisol [8]. Copeptin is a 39 amino-acid glycopeptide and is equivalent to the C-terminal part of pre-provasopressin [7]. Because copeptin is stable for days, it can be easily measured in blood samples [7]. Copeptin therefore is a surrogate marker for vasopressin release and might act as a marker for stress response [7]. The aim of this prospective study was to elucidate whether copeptin could be used as a marker for severity and prognosis of aSAH.

Materials and Methods

Patients with aSAH admitted to our neurosurgical unit from 21 December 2010 through 21 March 2011 were prospectively included. The study was approved by the Bern Canton Ethics Committee (Bern, Switzerland) and written informed consent was obtained from all patients (Clinical Trial Registration Information NCT00878813).

We collected demographic, clinical, radiological and outcome data for all patients. Venous blood was collected in ethylenediamine-tetraacetic acid (EDTA) tubes and centrifuged for 10 minutes at 1,500 × g. Serum was stored at −80°C. Copeptin measurements were performed using a validated chemiluminescence sandwich immunoassay (B.R.A.H.M.S MICROLUMIN, Thermo Fisher Scientific, B.R.A.H.M.S, Henningsdorf, Germany). The assay parameters of the B.R.A.H.M.S MICROLUMIN copeptin assay were as follows: detection range of 0.05 to 250 mmol/l, between-day coefficient of variation (CV) of <8%, within-day CV of <5%. The copeptin concentrations were normalized to the lower limit of the detection range using a standard curve. The mean CV of the between-run and within-run were 1.7% and 0.8%, respectively. The reference interval for copeptin was 0.16 ± 0.07 mmol/l (95% confidence interval). The correlation coefficient of the assay at the lower limit of the detection range was 0.999. The intra-assay CV was 2.5% at 1 mmol/l and 0.5% at the lower limit of the detection range. The inter-assay CV was 1.9% at 1 mmol/l and 0.7% at the lower limit of the detection range.

Copeptin measurements were performed at admission and at 6 months. The primary endpoint was the association of copeptin levels at admission with the WFNS grade score after resuscitation. Levels of copeptin were compared across clinical and radiological scores as well as between patients with ICH, intraventricular hemorrhage, hydrocephalus, vasospasm and ischemia. The study was approved by the Bern Canton Ethics Committee (Bern, Switzerland) and written informed consent was obtained from all patients (Clinical Trial Registration Information NCT00878813).

Citation: Fung C, De Marchis GM, Katan M, Seiler M, Arnold M, et al. (2013) Copeptin as a Marker for Severity and Prognosis of Aneurysmal Subarachnoid Hemorrhage. PLoS ONE 8(1): e53191. doi:10.1371/journal.pone.0053191

Editor: Felix Schlachetzki, University of Regensburg, Germany

Received July 19, 2012; Accepted November 29, 2012; Published January 11, 2013

Copyright: © 2013 Fung et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Bern University Hospital sponsored the study. Thermo Scientific B.R.A.H.M.S, Henningsdorf, Germany provided all copeptin assays. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Marleen Seiler is an employee of Thermo Fisher Scientific. Thermo Scientific B.R.A.H.M.S, Henningsdorf, Germany provided all copeptin assays. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

* E-mail: Juergen.beck@insel.ch

Introduction

For assessment of the severity of aneurysmal subarachnoid hemorrhage (aSAH), the World Federation of Neurological Surgeons (WFNS) grade is the current gold standard [1]. The condition of patients with aSAH may however be confounded by seizure, hydrocephalus or sedation [2]. Treatment decisions such as occlusion of an aneurysm are based on clinical grading [1]. Prediction of outcome remains difficult and complicates decision-making for active treatment [3]. Copeptin has evolved as a serum marker for the severity of disease and outcome of patients in spontaneous intracerebral hemorrhage (ICH), ischemic stroke and sepsis [4,5,6]. It is released in an equimolar ratio with vasopressin from a common precursor protein, pre-provasopressin [7]. Vasopressin is a hypothalamic hormone that is stimulated by adrenocorticotrophic hormone (ACTH) and production of cortisol [8]. Copeptin is a 39 amino-acid glycopeptide and is equivalent to the C-terminal part of pre-provasopressin [7]. Because copeptin is stable for days, it can be easily measured in blood samples [7]. Copeptin therefore is a surrogate marker for vasopressin release and might act as a marker for stress response [7]. The aim of this prospective study was to elucidate whether copeptin could be used as a marker for severity and prognosis of aSAH.

Materials and Methods

Patients with aSAH admitted to our neurosurgical unit from 21 December 2010 through 21 March 2011 were prospectively included. The study was approved by the Bern Canton Ethics Committee (Bern, Switzerland) and written informed consent was obtained from all patients (Clinical Trial Registration Information NCT00878813).

We collected demographic, clinical, radiological and outcome data for all patients. Venous blood was collected in ethylenediamine-tetraacetic acid (EDTA) tubes and centrifuged for 10 minutes at 1,500 × g. Serum was stored at −80°C. Copeptin measurements were performed using a validated chemiluminescence sandwich immunoassay (B.R.A.H.M.S MICROLUMIN, Thermo Fisher Scientific, B.R.A.H.M.S, Henningsdorf, Germany). The assay parameters of the B.R.A.H.M.S MICROLUMIN copeptin assay were as follows: detection range of 0.05 to 250 mmol/l, between-day coefficient of variation (CV) of <8%, within-day CV of <5%. The copeptin concentrations were normalized to the lower limit of the detection range using a standard curve. The mean CV of the between-run and within-run were 1.7% and 0.8%, respectively. The correlation coefficient of the assay at the lower limit of the detection range was 0.999. The intra-assay CV was 2.5% at 1 mmol/l and 0.5% at the lower limit of the detection range. The inter-assay CV was 1.9% at 1 mmol/l and 0.7% at the lower limit of the detection range. The copeptin concentrations were normalized to the lower limit of the detection range using a standard curve. The mean CV of the between-run and within-run were 1.7% and 0.8%, respectively. The correlation coefficient of the assay at the lower limit of the detection range was 0.999. The intra-assay CV was 2.5% at 1 mmol/l and 0.5% at the lower limit of the detection range. The inter-assay CV was 1.9% at 1 mmol/l and 0.7% at the lower limit of the detection range.

Citation: Fung C, De Marchis GM, Katan M, Seiler M, Arnold M, et al. (2013) Copeptin as a Marker for Severity and Prognosis of Aneurysmal Subarachnoid Hemorrhage. PLoS ONE 8(1): e53191. doi:10.1371/journal.pone.0053191

Editor: Felix Schlachetzki, University of Regensburg, Germany

Received July 19, 2012; Accepted November 29, 2012; Published January 11, 2013

Copyright: © 2013 Fung et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Bern University Hospital sponsored the study. Thermo Scientific B.R.A.H.M.S, Henningsdorf, Germany provided all copeptin assays. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Marleen Seiler is an employee of Thermo Fisher Scientific. Thermo Scientific B.R.A.H.M.S, Henningsdorf, Germany provided all copeptin assays. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

* E-mail: Juergen.beck@insel.ch
aminetetraacetic acid (EDTA) tubes on admission and a sample was analyzed for copeptin. Samples were placed on ice, centrifuged at 3000 g, and plasma aliquoted and frozen at −70°C. We analyzed copeptin levels using a validated commercial chemiluminescence sandwich immunoassay (Thermo Scientific B.R.A.H.M.S LIA CT-proAVP, B.R.A.H.M.S GmbH, Henningsdorf, Germany) [5].

For grading, the best Glasgow Coma Scale (GCS) after resuscitation in unsedated patients was used [1,9]. Imaging at admission was used to determine Fisher grade, volume of ICH and hydrocephalus [10,11]. Patients were divided into 2 groups: those with diffuse subarachnoid blood (Fisher grade 2 and 4), and patients with thick subarachnoid blood clot (Fisher grade 3). Admission CT angiography or digital subtraction angiography was used for aneurysm detection. Aneurysm location was divided into those originating from the anterior and posterior circulation [12]. Cerebral vasospasm and ischemic lesions were defined using the CONSCIOUS criteria [9]. Ischemic lesions were stratified into small (<10 mL), medium (10–100 mL) and large (>100 mL). Clinical outcome was evaluated at the 6-month follow-up visit and categorized according to the patient’s modified Rankin scale (mRS) score: a good outcome was defined as mRS 0–3 and a poor outcome as mRS 4–6.

The primary endpoint was the association of admission copeptin levels with WFNS grade. Fisher grade, ICH, intraventricular hemorrhage (IVH), hydrocephalus, vasospasm, ischemia and mortality were defined as secondary endpoints.

Comparisons of copeptin levels with clinical scales and endpoints were calculated using an unpaired Mann-Whitney-U test (StataCorp, College Station, TX, USA). Two-sided P-values<0.05 were considered significant.

**Results**

Our study included a total of 18 patients (12 women and 6 men), and the median age was 57 years (interquartile range (IQR) 48–67 years). Copeptin values and distributions are shown in Table 1 and Fig. 1. The overall median copeptin level at admission was 17.0 pmol/L (IQR 3.3–38.4). The median copeptin level was 6.8 pmol/L for patients WFNS 1 (n = 8), 2.8 pmol/L for WFNS 2 (n = 2), 7.1 pmol/L for WFNS 3 (n = 1), 17.4 pmol/L for WFNS 4 (n = 5) and 79.9 pmol/L for WFNS 5 (n = 2). Median intraparenchymal hematoma volume was 27.5 mL. Three patients developed ischemic lesions, all of which were assessed as small (<10 mL).

Higher copeptin levels were significantly associated with poor-grade (WFNS 4–5) aSAH, Fisher grade 3 and ICH (Table 1). 15 out of 18 patients had a proven aneurysm. Among the remaining 3 patients, one had a perimesencephal SAH, one died before an aneurysm could be detected, and in one patient – although having a SAH Fisher grade 3 – the aneurysm could not be proven. 11 aneurysms were located in the anterior and 4 in the posterior circulation. Aneurysm location was not significantly associated with copeptin levels (P = 0.38; Table 1). In addition, sex was not significantly associated with copeptin levels; the 6 male patients had a median copeptin level of 21.4 pmol/L compared to 7 pmol/L for the 12 female patients (Table 1). Copeptin levels in patients with a good outcome were lower than those with a poor outcome (P = 0.054, Table 1). Patients that died after aSAH had median copeptin levels three times higher than aSAH survivors at 6-months (P = 0.277).

**Discussion**

The main finding of the current study is that copeptin reflects the severity of aSAH, as assessed by the WFNS score after resuscitation and similarly to the grading of the severity of ischemic stroke [4]. The median copeptin level of our study cohort was comparable to reported median levels in cohorts with hemorrhagic stroke (16.3 pmol/L) and ischemic stroke (11.6 pmol/L) [4,6]. Median copeptin levels in healthy individuals have been reported, and range from 3.7 to 4.2 pmol/L [4,7,13]. In the current study, the presence of ICH in patients with aSAH was statistically significantly associated with higher levels of copeptin. Zweifel et al. showed that higher levels of copeptin in patients with ICH were associated with increased hematoma volume and poorer clinical outcome [6]. We have now demonstrated a similar relationship in aSAH patients; increased copeptin is significantly associated with the amount of subarachnoid blood. Due to the fact that the majority of poor grade SAH patients also display an ICH, the data must be interpreted with caution. Whether high levels of copeptin can be attributed solely to the severity of the SAH as rated by the WFNS grade or also to the occurrence of ICH cannot be answered. Yet in general, the occurrence of ICH has an impact on the severity of the clinical picture and outcome of SAH patients. We found no statistically significant association of copeptin with IVH, hydrocephalus, vasospasm, aneurysm location, sex, delayed ischemia, or mortality within 6 months, although there was a trend towards an association with functional outcome.

Delayed cerebral vasospasm is a well-recognized contributor to poor outcome [2,9]. The cascade of neurovascular events encompassing changes early after the ictus as well as delayed cerebral ischemia due to vasospasm determines final outcome. So far, biomarkers on admission fail to reliably predict delayed
cerebrovascular events [14]. In our opinion admission copeptin levels might not predict later cerebrovascular events, yet serial testing throughout the course of the disease might show an association. Still, in a recent retrospective analysis, Zhu et al. found a significant association between copeptin and vasospasm [15]. However, in line with our current results, they concluded that admission copeptin levels should not be used as a predictor for vasospasm because clinical grades had a higher accuracy [15].

Whether copeptin release is SAH specific or reflects a general stress response remains unclear. Copeptin is released from the hypothalamus in an equimolar ratio with vasopressin. The increase of copeptin in SAH patients might therefore rather result from activation of the hypothalamo-pituitary-adrenal axis as a response to stress [4]. This is very likely since, besides ischemic and hemorrhagic stroke, this has been shown for various diseases like respiratory tract infection, heart failure and shock [5,16,17]. Still, this does not exclude the role of copeptin as a potential biomarker for severity of SAH.

Despite the strength of the prospective protocol and the detailed patient characterization, our pilot study was too small to draw definitive conclusions. However the results of this study, as well as the similar findings by Zhu et al. [15], should encourage further investigation on copeptin in patients with aSAH.

Conclusions

Copeptin levels on admission were statistically significantly associated with severity of aSAH according to the WFNS grade, the amount of subarachnoid blood and ICH. Copeptin levels tended to be higher in patients with unfavorable clinical outcome.

Table 1. Copeptin levels and characteristics of study patients.

|                        | n   | Median copeptin level (IQR) (pmol/L) | p-value |
|------------------------|-----|-------------------------------------|---------|
| **WFNS grade**         |     |                                     |         |
| Good-grade             | 11  | 6.8 (6.6–17.4)                      |         |
| Poor-grade             | 7   | 26.3 (18.3–204)                     | P = 0.006 |
| **Fisher grade**       |     |                                     |         |
| Diffuse blood (Fisher grade 2 and 4) | 3   | 1.6 (1.5–3.3)                       |         |
| Thick clot (Fisher grade 3) | 15  | 18.3 (6.8–60.4)                     | P = 0.027 |
| **ICH**                |     |                                     |         |
| Yes                    | 6   | 52.5 (17.4–204)                     |         |
| No                     | 12  | 6.7 (2.2–22.3)                      | P = 0.02 |
| **IVH**                |     |                                     |         |
| Yes                    | 11  | 17.4 (6.6–38.4)                     |         |
| No                     | 7   | 7.1 (1.6–79.9)                      | P = 0.89 |
| **Hydrocephalus**      |     |                                     |         |
| Yes                    | 12  | 17.9 (5–32.4)                       |         |
| No                     | 6   | 6.7 (3.3–60.4)                      | P = 0.682 |
| **Vasospasm**          |     |                                     |         |
| Yes                    | 5   | 26.3 (24.5–60.4)                    |         |
| No                     | 13  | 7.1 (2.8–18.3)                      | P = 0.15 |
| **Ischemia**           |     |                                     |         |
| Yes                    | 3   | 24.5 (1.3–60.4)                     |         |
| No                     | 15  | 16.5 (3.3–38.4)                     | P = 1.0  |
| **Sex**                |     |                                     |         |
| Male                   | 6   | 21.4 (12.7–94.3)                    |         |
| Female                 | 12  | 7 (2.9–51.9)                        | P = 0.5  |
| **Aneurysm location**  |     |                                     |         |
| Anterior circulation   | 11  | 17.4 (6.8–60.4)                     |         |
| Posterior circulation  | 4   | 2.2 (1.4–29.5)                      | P = 0.38 |
| **Outcome**            |     |                                     |         |
| Good                   | 13  | 6.8 (2.8–24.5)                      |         |
| Poor                   | 5   | 26.3 (17.4–204)                     | P = 0.054 |
| **Mortality**          |     |                                     |         |
| Survivors              | 14  | 7.0 (2.8–38.4)                      |         |
| Deceased               | 4   | 21.9 (17–115.2)                     | P = 0.277 |

IQR: interquartile range; WFNS: World Federation of Neurological Surgeons; ICH: intracerebral hemorrhage; IVH: intraventricular hemorrhage.

*WFNS grade: Good-grade WFNS 1–3; Poor-grade: WFNS 4–5.

modified Rankin Scale (mRS) score 0–3: Good outcome; mRS 4–6: Poor outcome.

doi:10.1371/journal.pone.0053191.t001
Copeptin might therefore evolve as a useful marker for prognosis in subarachnoid hemorrhage.

Acknowledgments

Susan Wieting provided editing support, Bern University Hospital, Department of Neurosurgery, Publications Office, Bern, Switzerland.

Author Contributions

Conceived and designed the experiments: CF AR JB. Performed the experiments: CF GMDM MK MS MA JG AR JB. Analyzed the data: CF MS AR JB. Contributed reagents/materials/analysis tools: MS. Wrote the paper: CF AR JB.

References

1. Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. (1988) J Neurosurg 68:985–986.
2. Bederson JB, Connolly ES, Jr., Batjer HH, Dacey RG, Dion JE, et al. (2009) Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a Special Writing Group of the Stroke Council. Stroke 40: 994–1025.
3. Le Roux PD, Elliott JP, Newell DW, Grady MS, Winn HR (1996) Predicting outcome in poor-grade patients with subarachnoid hemorrhage: a retrospective review of 159 aggressively managed cases. J Neurosurg 85: 39–49.
4. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, et al. (2009) Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 66: 799–808.
5. Roggen F, Muller B, Schuck J, Bergmann A, Redl H, et al. (2007) Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 28: 219–226.
6. Zwoelf G, Katan M, Schuetz P, Siegemund M, Morgenthaler NG, et al. (2010) Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. BMC Neurol 10: 34.
7. Morgenthaler NG, Strock J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clinical chemistry 52: 112–119.
8. Volpi S, Rahadian-Diehl C, Aguilera G (2004) Vasopressinergic regulation of the hypothalamic pituitary adrenal axis and stress adaptation. Stress 7: 75–93.
9. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, et al. (2010) Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials. Neurocrit Care 13: 416–424.
10. Fisher CM, Kutler JP, Davis JM (1980) Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computed tomographic scanning. Neurosurgery 6 (1):1–9.
11. Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, et al. (1996) The ABCs of measuring intracerebral hemorrhage volumes. Stroke 27: 1304–1305.
12. Molyneux A, Kerr R, Stratton I, Sanderson P, Clarke M, et al. (2002) International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms; a randomised trial. Lancet 360:1267–1274.
13. Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, et al. (2007) C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute myocardial Infarction, Peptide (LAMP) study. Circulation 115:2103–2110.
14. Lackner P, Dietmann A, Beer R, Fischer M, Broensner G, et al. (2010) Cellular microparticles as a marker for cerebral vasospasm in spontaneous subarachnoid hemorrhage. Stroke 41: 2353–2357.
15. Zhu XD, Chen JS, Zhou F, Liu QC, Chen G, et al. (2011) Detection of copeptin in peripheral blood of patients with aneurysmal subarachnoid hemorrhage. Crit Care 15: R288.
16. Muller B, Morgenthaler N, Stolz D, Schuetz P, Muller C, et al. (2007) Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 37:145–152.
17. Stoiser B, Mored D, Hulsmann M, Berger R, Struck J, et al. (2006) Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 36:771–778.